-
Casein Kinase Related Products (93)
Related Products (93)
-
PI-828 (Standard)
0 ImagesCat. No.: HY-108606RCAS No.: 942289-87-4
-
Casein kinase 1δ-IN-30
0 ImagesCat. No.: HY-169677CAS No.: 849012-74-4Casein kinase 1δ-IN-30 (Compound 581) is a Casein kinase 1δ (CK1δ) inhibitor. Casein kinase 1δ-IN-30 can be used in the research of neurodegenerative diseases.
-
CK1δ-IN-5
0 ImagesCat. No.: HY-169713CAS No.: 956753-89-2CK1δ-IN-5 (Compound 24) is a Casein kinase 1δ (CK1δ) inhibitor. CK1δ-IN-5 can be used in the research of neurodegenerative diseases.
-
TBCA (Standard)
0 ImagesCat. No.: HY-110052RCAS No.: 934358-00-6TBCA (Standard) is the analytical standard of TBCA (HY-110052). This product is intended for research and analytical applications. TBCA is a highly selective CK2 (casein Kinase II) inhibitor with an IC50 of 110 nM and a Ki of 77 nM. TBCA shows selectivity for CK2 over CK1, DYRK1A and a panel of 27 other Kinases.
-
Casein Kinase II Inhibitor IV (Standard)
0 ImagesCat. No.: HY-111378RCAS No.: 863598-09-8Casein Kinase II Inhibitor IV (Standard) is the analytical standard of Casein Kinase II Inhibitor IV (HY-111378). This product is intended for research and analytical applications. Casein Kinase II Inhibitor IV is a potent, ATP-competitive of casein Kinase II inhibitor with an IC50 of 9 nM. Casein Kinase II Inhibitor IV ia also a human keratinocytes (NHEK) differentiation inducer.
-
CK1-IN-1 (Standard)
0 ImagesCat. No.: HY-111820RCAS No.: 1784751-20-7CK1-IN-1 (Standard) is the analytical standard of CK1-IN-1 (HY-111820). This product is intended for research and analytical applications. CK1-IN-1 (Compound 1c) is a casein Kinase 1 (CK1) inhibitor with IC50 values of 15 nM and 16 nM for CK1δ and CK1ε, respectively. CK1-IN-1 inhibits p38α MAPK with an IC50 of 73 nM. CK1-IN-1 can be used to study cardiomyogenesis.
-
Silmitasertib sodium salt (Standard)
0 ImagesSynonyms: CX-4945 sodium salt (Standard)Silmitasertib (sodium salt) (Standard) is the analytical standard of Silmitasertib (sodium salt). This product is intended for research and analytical applications. Silmitasertib sodium salt is an orally bioavailable, highly selective and potent CK2 inhibitor, with IC50 values of 1 nM against CK2α and CK2α'.
-
IWP-2 (Standard)
0 ImagesCat. No.: HY-13912RCAS No.: 686770-61-6IWP-2 (Standard) is the analytical standard of IWP-2 (HY-13912). This product is intended for research and analytical applications. IWP-2 is an inhibitor of Wnt processing and secretion with an IC50 of 27 nM. IWP-2 targets the membrane-bound O-acyltransferase porcupine (Porcn) and thus preventing a crucial Wnt ligand palmitoylation. IWP-2 is also an ATP-competitive CK1δ inhibitor with an IC50 of 40 nM for the gatekeeper mutant M82FCK1δ.
-
GW461484A
0 ImagesCat. No.: HY-172676CAS No.: 401815-65-4GW461484A is a small-molecule inhibitor targeting Candida albicans Yck2, with an IC50 of 0.11 µM. It exhibits antifungal activity against C. albicans with a MIC80 of 12.5 µM. GW461484A holds potential for research on fungal diseases, such as drug-resistant Candida infections.
-
Yck2-IN-1
0 ImagesCat. No.: HY-168998CAS No.: 401816-26-0Yck2-IN-1 (Compound 2a) is an inhibitor of the fungal Candida albicans Yck2 kinase. It exhibits an IC50 of approximately 80 nM against Yck2 and a MIC80 of 12.5 µM against C. albicans, with good metabolic stability (66% remaining in mouse liver microsomes). In a mouse model of drug-resistant candidiasis, Yck2-IN-1 significantly reduced fungal burden in the kidneys. Yck2-IN-1 holds promise for research in the field of antifungal infection.
-
Silmitasertib (Standard)
0 ImagesSynonyms: CX-4945 (Standard)Silmitasertib (Standard) is the analytical standard of Silmitasertib. This product is intended for research and analytical applications. Silmitasertib (CX-4945) is an orally bioavailable, highly selective and potent CK2 inhibitor, with IC50 values of 1 nM against CK2α and CK2α'.
-
CSNK2-IN-1
0 ImagesCat. No.: HY-163783CAS No.: 3105428-74-5CSNK2-IN-1 is a potent and selective CSNK2 inhibitor with IC50 of 1.7 nM and 0.66 nM for CSNK2A1 and CSNK2A2, respectively. CSNK2-IN-1 has antiviral activity against beta-coronaviruses such as SARS-CoV-2 and MHV. CSNK2-IN-1 has good solubility, metabolic stability, and low cytotoxicity, but its plasma concentration in vivo decreases rapidly and is insufficient to achieve pharmacological effects. CSNK2-IN-1 can be used in the research of antiviral drug development.
